Debido a la Pandemia por Coronavirus (COVID-19), la Sociedad Argentina de Reumatología pone a disposición de los usuarios de su página web, contenido científico acerca del COVID-19 en relación a enfermedades reumáticas y opciones terapéuticas.

Esta información estará en constante revisión y actualización acorde a los avances científicos y publicaciones tanto nacionales como internacionales.

A continuación iremos actualizando alguna páginas de referencia e información general sobre COVID-19 y también tendremos artículos y publicaciones categorizadas.

Artículos y publicaciones por categoría

Are my patients with rheumatic diseases at higher risk of COVID-19?

[Click aquí]

Coronaviruses and immunosuppressed patients. The facts during the third epidemic.

[Click aquí]

COVID-19: consider cytokine storm syndromes and immunosuppression

[Click aquí]

Clinical guide for the management of rheumatology patients during the coronavirus pandemic

[Click aquí]

COVID-19 - Identifying patients for shielding in England

[Click aquí]

Risk stratification of patients with autoimmune rheumatic diseases

[Click aquí]

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

[Click aquí]

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

[Click aquí]

The Rheumatologist's Role in Covid-19

[Click aquí]

Viral dynamics in mild and severe cases of COVID-19

[Click aquí]

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

[Click aquí]

COVID-19: the new challenge for rheumatologists

[Click aquí]

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial.

[Click aquí]

Temporal dynamics in viral shedding and transmissibility of COVID-19.

[Click aquí]

Rates of Co-infection Between SARS-CoV-2and Other Respiratory Pathogens.

[Click aquí]

CloroCovid-19 Study.

[Click aquí]

COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases.

[Click aquí]

Primer reporte de la Gloval Alliance Covid.

[Click aquí]

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

[Click aquí]

Being a rheumatologist and a patient with a rheumatic disease today: A perspective at the time of COVID-19

[Click aquí]

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

[Click aquí]

On the use of corticosteroids for 2019-nCoV pneumonia.

[Click aquí]

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

[Click aquí]

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19)

[Click aquí]

Therapeutic Algorith for COVID-19

[Click aquí]

Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine.

[Click aquí]

Comité de patología crítica cardiovascular. Informe Cloroquina o Hidroxicloroquina

[Click aquí]

Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2. Agencia Española de Medicamentos y Productos Sanitarios.

[Click aquí]

CRA Position Statement: COVID-19 and Hydroxychloroquine Supply

[Click aquí]

Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology

[Click aquí]

COVID-19 Drug Therapy – Potential Options

[Click aquí]

Clinical guide for the management of rheumatology patients during the coronavirus pandemic

[Click aquí]

Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology

[Click aquí]

Potential Public Health Harms of Rushing to Judgment | Annals of Internal Medicine | American College of Physicians

[Click aquí]

CRA Position Statement: COVID-19 and Hydroxychloroquine Supply (The Canadian Rheumatology Association)

[Click aquí]

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid- 19

[Click aquí]

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine fortheTreatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

[Click aquí]

Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019

[Click aquí]

Medical Societies Recommendations on Biologic use

[Click aquí]

Uso de hidroxicloroquina, Plaquenil® en el contexto de COVID 19 – Riesgo de prolongación del intervalo QT e interacciones entre fármacos y medicamentos

[Click aquí]

Anexo 1: Información más reciente sobre las interacciones con medicamentos y las precauciones de uso correspondientes

[Click aquí]

Clinical and microbiological effect of a combination of HCQ and AZITRO en 80 pte Francia Didier

[Click aquí]

Drug Evaluation during the Covid-19 Pandemic

[Click aquí]

EULAR: Hydroxychloroquine use in lupus patients ‘does not seem to prevent COVID-19’

[Click aquí]

Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists

[Click aquí]

Recomendaciones condicionales para el abordaje terapéutico de COVID-19

[Click aquí]

Recommendation Regarding the Use of Cloth Face Coverings | CDC

[Click aquí]

Recommendation Regarding the Use of Cloth Face Coverings

[Click aquí]

Recomendaciones condicionales para el abordaje terapéutico de COVID-19

[Click aquí]

Recomendaciones SAM y FMC-COVID-19

[Click aquí]

Información destacada sobre CORONAVIRUS

[Click aquí]

La Sar Informa

[Click aquí]

NUESTROS SPONSORS